Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Validate Roche s AmpliChip, Help Evaluate Leukemia Microarray

NEW YORK, July 25 (GenomeWeb News) - Laboratory Corporation of America will start validating Roche Diagnostics' AmpliChip CYP450 and will help Roche evaluate its research leukemia microarray, which is currently in development, the company said on Friday.

 

Roche's AmpliChip CYP450, which is built around Affymetrix's DNA chips, is designed to help physicians select dosing regimens for drugs covering a broad array of conditions, including cardiac diseases, chronic pain, cancer, and common psychiatric disorders.

 

Its leukemia microarray, which also uses AmpliChip technology, is designed to identify subclasses of leukemia.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.